{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:07:34Z","timestamp":1794618454166,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04394-6","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:11:21Z","timestamp":1748880681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["EZH-2 expression and prognostic significance in patients with low-grade non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Meryem","family":"\u015eener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin Derya","family":"Din\u00e7y\u00fcrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazl\u0131","family":"Totik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine K\u0131l\u0131\u00e7","family":"Ba\u011f\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Payda\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"G\u00fcrkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"1","key":"4394_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/leu.2013.288","volume":"28","author":"K Lund","year":"2014","unstructured":"Lund, K., Adams, P. D. & Copland, M. EZH-2 in normal and malignant hematopoiesis. Leukemia 28(1), 44\u201349 (2014).","journal-title":"Leukemia"},{"key":"4394_CR2","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2005-09-3585","volume":"107","author":"LM Kamminga","year":"2006","unstructured":"Kamminga, L. M. et al. The polycomb group gene EZH-2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170\u20132179 (2006).","journal-title":"Blood"},{"key":"4394_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.cell.2008.12.043","volume":"136","author":"E Ezhkova","year":"2009","unstructured":"Ezhkova, E. et al. EZH-2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136, 1122\u20131135 (2009).","journal-title":"Cell"},{"key":"4394_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","volume":"157","author":"FM Raaphorst","year":"2000","unstructured":"Raaphorst, F. M. et al. Coexpression of BMI-1 and EZH-2 polycomb group genes in Reed-Sternberg cells of Hodgkin\u2019s disease. Am. J. Pathol. 157, 709\u2013715 (2000).","journal-title":"Am. J. Pathol."},{"key":"4394_CR5","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1046\/j.1365-2141.2001.02641.x","volume":"112","author":"HP Visser","year":"2001","unstructured":"Visser, H. P. et al. The Polycomb group protein EZH-2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950\u2013958 (2001).","journal-title":"Br. J. Haematol."},{"key":"4394_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin, R. D. et al. Somatic mutations altering EZH-2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181\u2013185 (2010).","journal-title":"Nat. Genet."},{"key":"4394_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3324\/haematol.2010.028605","volume":"96","author":"D Sasaki","year":"2011","unstructured":"Sasaki, D. et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy. Haematologica 96, 712\u2013719 (2011).","journal-title":"Haematologica"},{"key":"4394_CR8","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","volume":"116","author":"I Velichutina","year":"2010","unstructured":"Velichutina, I. et al. EZH-2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116, 5247\u20135255 (2010).","journal-title":"Blood"},{"key":"4394_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0002-9440(10)64583-X","volume":"157","author":"FM Raaphorst","year":"2000","unstructured":"Raaphorst, F. M. et al. Coexpression of BMI-1 and EZH-2 polycomb group genes in Reed-Sternberg cells of Hodgkin\u2019s disease. Am. J. Pathol. 157, 709\u2013715 (2000).","journal-title":"Am. J. Pathol."},{"key":"4394_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1046\/j.1365-2141.2001.02641.x","volume":"112","author":"HP Visser","year":"2001","unstructured":"Visser, H. P. et al. The Polycomb group protein EZH-2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950\u2013958 (2001).","journal-title":"Br. J. Haematol."},{"issue":"12","key":"4394_CR11","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/leu.2013.94","volume":"27","author":"X Zhao","year":"2013","unstructured":"Zhao, X. et al. Disruption of the MYC-miRNA-EZH-2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 27(12), 2341\u20132350 (2013).","journal-title":"Leukemia"},{"issue":"1","key":"4394_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcmd.2014.07.013","volume":"54","author":"A Rabello Ddo","year":"2015","unstructured":"Rabello Ddo, A. et al. Overexpression of EZH-2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells Mol. Dis. 54(1), 97\u2013102 (2015).","journal-title":"Blood Cells Mol. Dis."},{"key":"4394_CR13","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","volume":"121","author":"J Yan","year":"2013","unstructured":"Yan, J. et al. EZH-2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 121, 4512\u20134520 (2013).","journal-title":"Blood"},{"issue":"5","key":"4394_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano, A. et al. Tazemetostat, an EZH-2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19(5), 649\u2013659 (2018).","journal-title":"Lancet Oncol."},{"issue":"8","key":"4394_CR15","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","volume":"115","author":"CH Geisler","year":"2010","unstructured":"Geisler, C. H. et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115(8), 1530\u20131533 (2010).","journal-title":"Blood"},{"issue":"27","key":"4394_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. oncol. 32(27), 3059 (2014).","journal-title":"J. Clin. oncol."},{"issue":"2","key":"4394_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/ehm.11.82","volume":"5","author":"P Morel","year":"2012","unstructured":"Morel, P. & Merlini, G. Owen, Swerdlow, Facon Garcia-Sanz. Risk stratification in Waldenstr\u00f6m macroglobulinemia. Exp. Rev. Hematol. 5(2), 187\u2013199 (2012).","journal-title":"Exp. Rev. Hematol."},{"issue":"9","key":"4394_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 16(9), 1111\u20131122 (2015).","journal-title":"Lancet Oncol."},{"issue":"15","key":"4394_CR19","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1080\/17568919.2024.2380243","volume":"16","author":"P Wei","year":"2024","unstructured":"Wei, P., Mei, D., Hu, S. & Du, S. Dual-target EZH-2 inhibitor: latest advances in medicinal chemistry. Future Med. Chem. 16(15), 1561\u20131582 (2024).","journal-title":"Future Med. Chem."},{"issue":"20","key":"4394_CR20","first-page":"3735","volume":"125","author":"SQ Guo","year":"2012","unstructured":"Guo, S. Q. & Zhang, Y. Z. Overexpression of enhancer of zests homolog 2 in lymphoma. Chin. Med. J. (Engl). 125(20), 3735\u20133739 (2012).","journal-title":"Chin. Med. J. (Engl)."},{"issue":"9","key":"4394_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","volume":"29","author":"X Tian","year":"2016","unstructured":"Tian, X., Pelton, A., Shahsafaei, A. & Dorfman, D. M. Differential expression of enhancer of zeste homolog 2 (EZH-2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH-2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas. Mod. Pathol. 29(9), 1050\u20131057 (2016).","journal-title":"Mod. Pathol."},{"issue":"4","key":"4394_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet, S. et al. EZH-2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 7(4), e555 (2017).","journal-title":"Blood Cancer J."},{"issue":"4","key":"4394_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s13691-024-00716-z","volume":"13","author":"S Kikuchi","year":"2024","unstructured":"Kikuchi, S. et al. Complete response using the EZH-2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase. Int. Cancer Conf J. 13(4), 488\u2013492 (2024).","journal-title":"Int. Cancer Conf J."},{"key":"4394_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.humpath.2018.08.025","volume":"83","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Aberrant differential expression of EZH-2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis. Hum. Pathol. 83, 166\u2013176 (2019).","journal-title":"Hum. Pathol."},{"key":"4394_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115769","volume":"216","author":"Y Budagaga","year":"2023","unstructured":"Budagaga, Y. et al. Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. Biochem. Pharmacol. 216, 115769 (2023).","journal-title":"Biochem. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04394-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04394-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04394-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:11:22Z","timestamp":1748880682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04394-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04394-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"was obtained from all patients, and approval for this study was obtained from the Ethical Committee of Cukurova University Medical School Hospital, Adana, Turkey. I confirm that all methods have been carried out in accordance with relevant guidelines and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"19329"}}